Pilatus Biosciences
Biopharmaceutical company (founded 2022) developing biologics that target metabolic checkpoints to reprogram the tumor microenvironment. Operates R&D across Switzerland and Taiwan and advances lead antibody and bifunctional programs through late-stage preclinical studies toward IND and first-in-human studies. Uses academic and industry collaborations, patent licensing, peer-reviewed publication, and conference dissemination to support translational oncology development. Public materials report favorable preclinical safety and manufacturability for lead biologic candidates.
Industries
N/A
Nr. of Employees
small (1-50)
Pilatus Biosciences
Pilatus Biosciences SA, Route de la Corniche 6, 1066 Epalinges, Vaud, Switzerland; Pilatus Biosciences Corp, 17F-1, No. 508, Section 7, Zhongxiao East Road, Nangang District, Taipei City 115, Taiwan; Pilatus Biosciences Inc, 874 Walker Road, Suite C, Dover, Delaware 19904, USA
Products
PLT012 (anti-CD36 monoclonal antibody)
Humanized monoclonal antibody that blocks CD36-mediated lipid uptake to modulate immunosuppressive cells and enhance intratumoral cytotoxic immune responses; progressed through late-stage preclinical studies toward IND.
PLT011 (PD-L1 / IL-10 bifunctional protein)
PD-L1 antibody–IL-10 fusion protein designed to localize IL-10 activity to the tumor microenvironment to reinvigorate exhausted CD8+ T cells while blocking PD-L1-mediated suppression; demonstrated preclinical efficacy in hepatocellular carcinoma and melanoma models.
PLT212 (discovery-stage program)
Discovery-stage program; target and details not disclosed in public materials.
PLT012 (anti-CD36 monoclonal antibody)
Humanized monoclonal antibody that blocks CD36-mediated lipid uptake to modulate immunosuppressive cells and enhance intratumoral cytotoxic immune responses; progressed through late-stage preclinical studies toward IND.
PLT011 (PD-L1 / IL-10 bifunctional protein)
PD-L1 antibody–IL-10 fusion protein designed to localize IL-10 activity to the tumor microenvironment to reinvigorate exhausted CD8+ T cells while blocking PD-L1-mediated suppression; demonstrated preclinical efficacy in hepatocellular carcinoma and melanoma models.
PLT212 (discovery-stage program)
Discovery-stage program; target and details not disclosed in public materials.
Services
Pursues co-development, licensing, and strategic partnerships to advance pipeline programs and expand global reach.
Facilitates research collaborations, material and clinical supply partnerships, and translational research agreements with academic and clinical centers and industry partners.
Pursues co-development, licensing, and strategic partnerships to advance pipeline programs and expand global reach.
Facilitates research collaborations, material and clinical supply partnerships, and translational research agreements with academic and clinical centers and industry partners.
Expertise Areas
- Immunometabolism and metabolic checkpoint biology
- Therapeutic monoclonal antibody development
- Bifunctional antibody–cytokine fusion protein development
- Preclinical efficacy and translational assay development
Key Technologies
- Monoclonal antibody engineering
- Antibody–cytokine fusion protein engineering
- In vivo murine tumor models
- Ex vivo human tumor assays
News & Updates
Poster presentation reporting mechanism-of-action and preclinical activity of a CD36-targeting antibody (poster available upon request).
Poster presentations on CD36-targeting antibody and metabolic reprogramming in the tumor microenvironment (posters available upon request).
Poster presentations on metabolic approaches to reprogram the tumor microenvironment using CD36-targeting strategies (posters available upon request).
Oral and poster presentations on CD36-targeting antibody research demonstrating immunometabolic approaches to reprogram tumor microenvironment.
Poster presentation of preclinical data demonstrating durable anti-tumor immunity induced by a CD36-targeting antibody via immunometabolic reprogramming (poster #1205).
Peer-reviewed preclinical study describing mechanism and efficacy of a CD36-targeting antibody in liver cancer and liver metastasis; supports CD36 as an immunometabolic checkpoint.
Poster presentation reporting mechanism-of-action and preclinical activity of a CD36-targeting antibody (poster available upon request).
Poster presentations on CD36-targeting antibody and metabolic reprogramming in the tumor microenvironment (posters available upon request).
Poster presentations on metabolic approaches to reprogram the tumor microenvironment using CD36-targeting strategies (posters available upon request).
Oral and poster presentations on CD36-targeting antibody research demonstrating immunometabolic approaches to reprogram tumor microenvironment.
Poster presentation of preclinical data demonstrating durable anti-tumor immunity induced by a CD36-targeting antibody via immunometabolic reprogramming (poster #1205).
Peer-reviewed preclinical study describing mechanism and efficacy of a CD36-targeting antibody in liver cancer and liver metastasis; supports CD36 as an immunometabolic checkpoint.